EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

In vitro and in vivo model systems for Orthoflavivirus antiviral therapeutics: current landscape and strategic considerations

Marnix Van Loock, Tobias Nilsson, James F Demarest, Timothy Tellinghuisen, Ruxandra Draghia-Akli iD

Journal of Virology · 2026

DOI: 10.1128/jvi.01011-26 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Virology, 2026. Verfasst von Marnix Van Loock und 4 weiteren Autor:innen. Beteiligte Einrichtung: 1ML Consultancy BV, Begijnendijk, Belgium. Hauptthemen laut MEDLINE: Antiviral Agents, Flavivirus, Flavivirus Infections, Flaviviridae Infections. Die Arbeit nennt 207 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Orthoflaviviruses represent an escalating global health challenge, encompassing a diverse group of arthropod-borne viruses that cause substantial morbidity and mortality worldwide. A critical bottleneck in drug discovery is identifying in vitro and in vivo models that accurately recapitulate human pathophysiology while remaining practical for high-throughput screening and medicinal chemistry efforts. Despite substantial preclinical activity, the paucity of clinically advanced Orthoflavivirus (hereafter referred to as flaviviruses) antivirals underscores the need for improved discovery paradigms. Refinement of antiviral assays, informed by viral biology and guided by rigorous validation principles, will be central to identifying robust small-molecule inhibitors. The convergence of high-quality phenotypic assays, precise target-based methods, and physiologically relevant models offers a promising path forward for flavivirus drug discovery and development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiviral AgentsFlavivirusFlavivirus InfectionsFlaviviridae InfectionsAnimalsHumansDrug DiscoveryDisease Models, AnimalDrug Evaluation, PreclinicalHigh-Throughput Screening AssaysVirus Replication

Stichwörter der Autor:innen

animal modelsassayflavivirussmall molecule antiviral

Substanzen

Antiviral Agents

Autor:innen und Institutionen

  • 1ML Consultancy BV, Begijnendijk, Belgium.
  • Infectious Diseases Discovery, Pharma Research and Early Development (pRED), F. Hoffmann-La Roche Ltd., Basel, Switzerland.
  • INTREPID Alliance, Cambridge, Massachusetts, USA.

ORCID-Profile: Ruxandra Draghia-Akli

Zitieren

APA

Van Loock, M., Nilsson, T., Demarest, J. F., Tellinghuisen, T., & Draghia-Akli, R. (2026). In vitro and in vivo model systems for Orthoflavivirus antiviral therapeutics: current landscape and strategic considerations. Journal of Virology. https://doi.org/10.1128/jvi.01011-26

Vancouver

Van Loock M, Nilsson T, Demarest JF, Tellinghuisen T, Draghia-Akli R. In vitro and in vivo model systems for Orthoflavivirus antiviral therapeutics: current landscape and strategic considerations. Journal of Virology. 2026. doi:10.1128/jvi.01011-26

BibTeX
@article{VanLoock2026,
  author = {Van Loock, Marnix and Nilsson, Tobias and Demarest, James F and Tellinghuisen, Timothy and Draghia-Akli, Ruxandra},
  title = {In vitro and in vivo model systems for Orthoflavivirus antiviral therapeutics: current landscape and strategic considerations},
  journal = {Journal of Virology},
  year = {2026},
  doi = {10.1128/jvi.01011-26}
}
Kostenlos starten →